Skandinaviska Enskilda Banken (SEB)
DYN icon

Skandinaviska Enskilda Banken (SEB)’s Dyne Therapeutics DYN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,816
Closed -$280K – 857
2025
Q1 		$280K Hold
26,816
– – ﹤0.01% 731
2024
Q4 		$634K Buy
+26,816
New +$793K ﹤0.01% 697

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s DYN Position: Q2 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 26,816 shares — an estimated $280K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in DYN in Q4 2024 and held it in 2 quarters. The position peaked at $634K in Q4 2024. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 26,816 Dyne Therapeutics shares in Q2 2025, an estimated $280K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Dyne Therapeutics in Q4 2024 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Dyne Therapeutics position peaked at $634K in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2025, filed 13 Aug 2025.